
JBIO Stock Forecast & Price Target
JBIO Analyst Ratings
Bulls say
Jade Biosciences Inc. is projected to achieve significant risk-adjusted revenue growth from its lead candidate, JADE101, with estimates increasing from $80 million in 2031 to $926 million by 2037, representing a compound annual growth rate (CAGR) of 23%. The company’s advanced research indicates that JADE101 demonstrates improved potency, affinity, and half-life compared to existing therapies, which could result in better efficacy and safety for patients. With a solid pipeline including JADE201 and JADE301, along with multiple anticipated value-inflection points, there is a strong foundation for sustained financial performance and long-term growth in the biotech sector.
Bears say
Jade Biosciences faces significant risks that could hinder its financial performance and market potential, particularly if it struggles to commercialize its therapies or achieve expected product uptake. The company reported a substantial net loss of $25 million in the third quarter of 2025, which raises concerns about its ongoing financial viability and ability to sustain operations. Additionally, delays in clinical development or regulatory approvals for its main candidates, JADE101 and JADE201, could severely impede Jade's revenue generation capabilities and overall valuation.
This aggregate rating is based on analysts' research of Aerovate Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
JBIO Analyst Forecast & Price Prediction
Start investing in JBIO
Order type
Buy in
Order amount
Est. shares
0 shares